Effect of statin therapy on the progression of coronary atherosclerosis

BMC Cardiovascular Disorders

Volumn 12, Issue , 2012, Pages

  Tian, Jinwei ^a   Gu, Xia ^a   Sun, Yanli ^a   Ban, Xiang ^b   Xiao, Yun ^b   Hu, Sining ^a   Yu, Bo ^a  

^a THE SECOND AFFILIATED HOSPITAL OF HARBIN MEDICAL UNIVERSITY   (China)

^b HARBIN MEDICAL UNIVERSITY   (China)

Author keywords

Atherosclerosis; Intravascular ultrasound; Meta analysis; Statin

Indexed keywords

ATORVASTATIN; CALCIUM; FLUINDOSTATIN; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; LOW DENSITY LIPOPROTEIN CHOLESTEROL; PITAVASTATIN; PRAVASTATIN; ROSUVASTATIN; SIMVASTATIN;

ACUTE CORONARY SYNDROME; ARTICLE; CORONARY ARTERY ATHEROSCLEROSIS; DISEASE COURSE; DRUG EFFECT; DRUG EFFICACY; DRUG USE; FOLLOW UP; HUMAN; META ANALYSIS; PRIORITY JOURNAL; STABLE ANGINA PECTORIS; TREATMENT DURATION;

BIOLOGICAL MARKERS; CHOLESTEROL, LDL; CORONARY ARTERY DISEASE; CORONARY VESSELS; DISEASE PROGRESSION; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; PLAQUE, ATHEROSCLEROTIC; TIME FACTORS; TREATMENT OUTCOME; ULTRASONOGRAPHY, INTERVENTIONAL;

EID: 84865537236     PISSN: None     EISSN: 14712261     Source Type: Journal    
DOI: 10.1186/1471-2261-12-70     Document Type: Article

References (73)

1. Collins R, Armitage J, Parish S, Sleigh P, Peto R. MRC/BHF Heart Protection Study of cholesterol-lowering with simvastatin in 5963 people with diabetes: a randomised placebo-controlled trial. Lancet 2003, 361:2005-2016.
2. Cannon CP, Braunwald E, McCabe CH, Rader DJ, Rouleau JL, Belder R, Joyal SV, Hill KA, Pfeffer MA, Skene AM. Intensive versus moderate lipid lowering with statins after acute coronary syndromes. N Engl J Med 2004, 350:1495-1504. 10.1056/NEJMoa040583, 15007110.
3. Ridker PM, Danielson E, Fonseca FA, Genest J, Gotto AM, Kastelein JJ, Koenig W, Libby P, Lorenzatti AJ, Macfadyen JG, Nordestgaard BG, Shepherd J, Willerson JT, Glynn RJ. Reduction in C-reactive protein and LDL cholesterol and cardiovascular event rates after initiation of rosuvastatin: a prospective study of the JUPITER trial. Lancet 2009, 373:1175-1182. 10.1016/S0140-6736(09)60447-5, 19329177.
4. Scott G, Diane B, Luther C, Richard C, Margo D, Wm H, Donald H, Illingworth DR, Russell L, Patrick M, James M, Richard P, Neil S, Linda H. Executive Summary of The Third Report of The National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, And Treatment of High Blood Cholesterol In Adults (Adult Treatment Panel III). JAMA 2001, 285:2486-2497. 10.1001/jama.285.19.2486, 11368702.
5. Simoons L, Saelman M. Effect of simvastatin on coronary atheroma: the Multicentre Anti-Atheroma Study (MAAS). Lancet 1994, 344:633-638. 10.1016/S0140-6736(94)92082-6, 7864934.
6. Rodriguez-Granillo GA, Agostoni P, Garcia-Garcia HM, Biondi-Zoccai GG, McFadden E, Amoroso G, de Jaegere P, Bruining N, de Feyter P, Serruys PW. Meta-analysis of the studies assessing temporal changes in coronary plaque volume using intravascular ultrasound. Am J Cardiol 2007, 99:5-10. 10.1016/j.amjcard.2006.07.054, 17196453.
7. Shiota M, Kusakabe H, Hikita Y, Nakao T, Izumi Y, Iwao H. Pharmacogenomics of cardiovascular pharmacology: molecular network analysis in pleiotropic effects of statin - an experimental elucidation of the pharmacologic action from protein-protein interaction analysis. J Pharmacol Sci 2008, 107:15-19. 10.1254/jphs.08R01FM, 18490854.
8. Toi T, Taguchi I, Yoneda S, Kageyama M, Kikuchi A, Tokura M, Kanaya T, Abe S, Matsuda R, Kaneko N. Early effect of lipid-lowering therapy with pitavastatin on regression of coronary atherosclerotic plaque. Comparison with atorvastatin. Circ J 2009, 73:1466-1472. 10.1253/circj.CJ-08-1051, 19531899.
9. Luscher TF, Pieper M, Tendera M, Vrolix M, Rutsch W, van den Branden F, Gil R, Bischoff KO, Haude M, Fischer D, Meinertz T, Münzel T. A randomized placebo-controlled study on the effect of nifedipine on coronary endothelial function and plaque formation in patients with coronary artery disease: the ENCORE II study. Eur Heart J 2009, 30:1590-1597. 10.1093/eurheartj/ehp151, 3295238, 19474053.
10. Takayama T, Hiro T, Yamagishi M, Daida H, Hirayama A, Saito S, Yamaguchi T, Matsuzaki M. Effect of rosuvastatin on coronary atheroma in stable coronary artery disease: multicenter coronary atherosclerosis study measuring effects of rosuvastatin using intravascular ultrasound in Japanese subjects (COSMOS). Circ J 2009, 73:2110-2117. 10.1253/circj.CJ-09-0358, 19801853.
11. Rodes-Cabau J, Tardif JC, Cossette M, Bertrand OF, Ibrahim R, Larose E, Gregoire J, L'Allier PL, Guertin MC. Acute effects of statin therapy on coronary atherosclerosis following an acute coronary syndrome. Am J Cardiol 2009, 104:750-757. 10.1016/j.amjcard.2009.05.009, 19733706.
12. Hiro T, Kimura T, Morimoto T, Miyauchi K, Nakagawa Y, Yamagishi M, Ozaki Y, Kimura K, Saito S, Yamaguchi T, Daida H, Matsuzaki M. Effect of intensive statin therapy on regression of coronary atherosclerosis in patients with acute coronary syndrome: a multicenter randomized trial evaluated by volumetric intravascular ultrasound using pitavastatin versus atorvastatin (JAPAN-ACS [Japan assessment of pitavastatin and atorvastatin in acute coronary syndrome] study). J Am Coll Cardiol 2009, 54:293-302. 10.1016/j.jacc.2009.04.033, 19608026.
13. Nasu K, Tsuchikane E, Katoh O, Tanaka N, Kimura M, Ehara M, Kinoshita Y, Matsubara T, Matsuo H, Asakura K, Asakura Y, Terashima M, Takayama T, Honye J, Hirayama A, Saito S, Suzuki T. Effect of fluvastatin on progression of coronary atherosclerotic plaque evaluated by virtual histology intravascular ultrasound. JACC Cardiovasc Interv 2009, 2:689-696.
14. Hong MK, Park DW, Lee CW, Lee SW, Kim YH, Kang DH, Song JK, Kim JJ, Park SW, Park SJ. Effects of statin treatments on coronary plaques assessed by volumetric virtual histology intravascular ultrasound analysis. JACC Cardiovasc Interv 2009, 2:679-688. 10.1016/j.jcin.2009.03.015, 19628193.
15. Yamada T, Azuma A, Sasaki S, Sawada T, Matsubara H. Randomized evaluation of atorvastatin in patients with coronary heart disease: a serial intravascular ultrasound study. Circ J 2007, 71:1845-1850. 10.1253/circj.71.1845, 18037734.
16. Nissen SE, Nicholls SJ, Sipahi I, Libby P, Raichlen JS, Ballantyne CM, Davignon J, Erbel R, Fruchart JC, Tardif JC, Schoenhagen P, Crowe T, Cain V, Wolski K, Goormastic M, Tuzcu EM. Effect of very high-intensity statin therapy on regression of coronary atherosclerosis: the ASTEROID trial. JAMA 2006, 295:1556-1565. 10.1001/jama.295.13.jpc60002, 16533939.
17. Tani S, Watanabe I, Anazawa T, Kawamata H, Tachibana E, Furukawa K, Sato Y, Nagao K, Kanmatsuse K, Kushiro T. Effect of pravastatin on malondialdehyde-modified low-density lipoprotein levels and coronary plaque regression as determined by three-dimensional intravascular ultrasound. Am J Cardiol 2005, 96:1089-1094. 10.1016/j.amjcard.2005.05.069, 16214443.
18. Yokoyama M, Komiyama N, Courtney BK, Nakayama T, Namikawa S, Kuriyama N, Koizumi T, Nameki M, Fitzgerald PJ, Komuro I. Plasma low-density lipoprotein reduction and structural effects on coronary atherosclerotic plaques by atorvastatin as clinically assessed with intravascular ultrasound radio-frequency signal analysis: a randomized prospective study. Am Heart J 2005, 150:287.
19. Kawasaki M, Sano K, Okubo M, Yokoyama H, Ito Y, Murata I, Tsuchiya K, Minatoguchi S, Zhou X, Fujita H, Fujiwara H. Volumetric quantitative analysis of tissue characteristics of coronary plaques after statin therapy using three-dimensional integrated backscatter intravascular ultrasound. J Am Coll Cardiol 2005, 45:1946-1953. 10.1016/j.jacc.2004.09.081, 15963391.
20. Petronio AS, Amoroso G, Limbruno U, Papini B, De Carlo M, Micheli A, Ciabatti N, Mariani M. Simvastatin does not inhibit intimal hyperplasia and restenosis but promotes plaque regression in normocholesterolemic patients undergoing coronary stenting: a randomized study with intravascular ultrasound. Am Heart J 2005, 149:520-526. 10.1016/j.ahj.2004.10.032, 15864242.
21. Nishioka H, Shimada K, Kataoka T, Hirose M, Asawa K, Hasegawa T, Yamashita H, Ehara S, Kamimori K, Sakamoto T, Kobayashi Y, Yoshimura T, Yoshiyama M, Takeuchi K, Yoshikawa J. Impact of HMG-CoA reductase inhibitors for non-treated coronary segments. Osaka City Med J 2004, 50:61-68.
22. Okazaki S, Yokoyama T, Miyauchi K, Shimada K, Kurata T, Sato H, Daida H. Early statin treatment in patients with acute coronary syndrome: demonstration of the beneficial effect on atherosclerotic lesions by serial volumetric intravascular ultrasound analysis during half a year after coronary event: the ESTABLISH Study. Circulation 2004, 110:1061-1068. 10.1161/01.CIR.0000140261.58966.A4, 15326073.
23. Jensen LO, Thayssen P, Pedersen KE, Stender S, Haghfelt T. Regression of coronary atherosclerosis by simvastatin: a serial intravascular ultrasound study. Circulation 2004, 110:265-270. 10.1161/01.CIR.0000135215.75876.41, 15238460.
24. Nissen SE, Tuzcu EM, Schoenhagen P, Brown BG, Ganz P, Vogel RA, Crowe T, Howard G, Cooper CJ, Brodie B, Grines CL, DeMaria AN. Effect of intensive compared with moderate lipid-lowering therapy on progression of coronary atherosclerosis: a randomized controlled trial. JAMA 2004, 291:1071-1080. 10.1001/jama.291.9.1071, 14996776.
25. Schartl M, Bocksch W, Koschyk DH, Voelker W, Karsch KR, Kreuzer J, Hausmann D, Beckmann S, Gross M. Use of Intravascular Ultrasound to Compare Effects of Different Strategies of Lipid-Lowering Therapy on Plaque Volume and Composition in Patients With Coronary Artery Disease. Circulation 2001, 104:387-392. 10.1161/hc2901.093188, 11468198.
26. Nissen SE, Tardif JC, Nicholls SJ, Revkin JH, Shear CL, Duggan WT, Ruzyllo W, Bachinsky WB, Lasala GP, Tuzcu EM. Effect of torcetrapib on the progression of coronary atherosclerosis. N Engl J Med 2007, 356:1304-1316. 10.1056/NEJMoa070635, 17387129.
27. Lee K, Ahn TH, Kang WC, Han SH, Choi IS, Shin EK. The effects of statin and niacin on plaque stability, plaque regression, inflammation and oxidative stress in patients with mild to moderate coronary artery stenosis. Korean Circ J 2011, 41:641-648. 10.4070/kcj.2011.41.11.641, 3242018, 22194758.
28. Kovarnik T, Mintz GS, Skalicka H, Kral A, Horak J, Skulec R, Uhrova J, Martasek P, Downe RW, Wahle A, Sonka M, Mrazek V, Aschermann M, Linhart A. Virtual histology evaluation of atherosclerosis regression during atorvastatin and ezetimibe administration: HEAVEN study. Circ J 2012, 76:176-183. 10.1253/circj.CJ-11-0730, 22076422.
29. Hirayama A, Saito S, Ueda Y, Takayama T, Honye J, Komatsu S, Yamaguchi O, Li Y, Yajima J, Nanto S, Takazawa K, Kodama K. Plaque-stabilizing effect of atorvastatin is stronger for plaques evaluated as more unstable by angioscopy and intravenous ultrasound. Circ J 2011, 75:1448-1454. 10.1253/circj.CJ-10-1035, 21502706.
30. Hong YJ, Jeong MH, Hachinohe D, Ahmed K, Choi YH, Cho SH, Hwang SH, Ko JS, Lee MG, Park KH, Sim DS, Yoon NS, Yoon HJ, Kim KH, Park HW, Kim JH, Ahn Y, Cho JG, Park JC, Kang JC. Comparison of effects of rosuvastatin and atorvastatin on plaque regression in Korean patients with untreated intermediate coronary stenosis. Circ J 2011, 75:398-406. 10.1253/circj.CJ-10-0658, 21157106.
31. Nicholls SJ, Ballantyne CM, Barter PJ, Chapman MJ, Erbel RM, Libby P, Raichlen JS, Uno K, Borgman M, Wolski K, Nissen SE. Effect of two intensive statin regimens on progression of coronary disease. N Engl J Med 2011, 365:2078-2087. 10.1056/NEJMoa1110874, 22085316.
32. Nair A, Kuban BD, Tuzcu EM, Schoenhagen P, Nissen SE, Vince DG. Coronary plaque classification with intravascular ultrasound radiofrequency data analysis. Circulation 2002, 106:2200-2206. 10.1161/01.CIR.0000035654.18341.5E, 12390948.
33. Nasu K, Tsuchikane E, Katoh O, Vince DG, Virmani R, Surmely JF, Murata A, Takeda Y, Ito T, Ehara M, Matsubara T, Terashima M, Suzuki T. Accuracy of in vivo coronary plaque morphology assessment: a validation study of in vivo virtual histology compared with in vitro histopathology. J Am Coll Cardiol 2006, 47:2405-2412. 10.1016/j.jacc.2006.02.044, 16781367.
34. DerSimonian R, Laird N. Meta-analysis in clinical trials. Control Clin Trials 1986, 7:177-188. 10.1016/0197-2456(86)90046-2, 3802833.
35. Rosenberg MS. The file-drawer problem revisited: a general weighted method for calculating fail-safe numbers in meta-analysis. Evolution 2005, 59:464-468.
36. Zhao XQ, Dong L, Hatsukami T, Phan BA, Chu B, Moore A, Lane T, Neradilek MB, Polissar N, Monick D, Lee C, Underhill H, Yuan C. MR imaging of carotid plaque composition during lipid-lowering therapy a prospective assessment of effect and time course. JACC Cardiovasc Imaging 2011, 4:977-986. 10.1016/j.jcmg.2011.06.013, 21920335.
37. Williams JK, Sukhova GK, Herrington DM, Libby P. Pravastatin has cholesterol-lowering independent effects on the artery wall of atherosclerotic monkeys. J Am Coll Cardiol 1998, 31:684-691. 10.1016/S0735-1097(97)00537-8, 9502654.
38. Shiomi M, Ito T, Tsukada T, Yata T, Watanabe Y, Tsujita Y, Fukami M, Fukushige J, Hosokawa T, Tamura A. Reduction of serum cholesterol levels alters lesional composition of atherosclerotic plaques. Effect of pravastatin sodium on atherosclerosis in mature WHHL rabbits. Arterioscler Thromb Vasc Biol 1995, 15:1938-1944. 10.1161/01.ATV.15.11.1938, 7583574.
39. Zhou G, Ge S, Liu D, Xu G, Zhang R, Yin Q, Zhu W, Chen J, Liu X. Atorvastatin reduces plaque vulnerability in an atherosclerotic rabbit model by altering the 5-lipoxygenase pathway. Cardiology 2010, 115:221-228. 10.1159/000296017, 20234134.
40. Jang IK, Tearney GJ, MacNeill B, Takano M, Moselewski F, Iftima N, Shishkov M, Houser S, Aretz HT, Halpern EF, Bouma BE. In vivo characterization of coronary atherosclerotic plaque by use of optical coherence tomography. Circulation 2005, 111:1551-1555. 10.1161/01.CIR.0000159354.43778.69, 2785437, 15781733.
41. Burke AP, Farb A, Malcom GT, Liang YH, Smialek J, Virmani R. Coronary risk factors and plaque morphology in men with coronary disease who died suddenly. N Engl J Med 1997, 336:1276-1282. 10.1056/NEJM199705013361802, 9113930.
42. Motoyama S, Kondo T, Sarai M, Sugiura A, Harigaya H, Sato T, Inoue K, Okumura M, Ishii J, Anno H, Virmani R, Ozaki Y, Hishida H, Narula J. Multislice computed tomographic characteristics of coronary lesions in acute coronary syndromes. J Am Coll Cardiol 2007, 50:319-326. 10.1016/j.jacc.2007.03.044, 17659199.
43. van Lammeren GW, Reichmann BL, Moll FL, Bots ML, de Kleijn DP, de Vries JP, Pasterkamp G, de Borst GJ. Atherosclerotic plaque vulnerability as an explanation for the increased risk of stroke in elderly undergoing carotid artery stenting. Stroke 2011, 42:2550-2555. 10.1161/STROKEAHA.110.607382, 21737811.
44. Falk E, Shah PK, Fuster V. Coronary plaque disruption. Circulation 1995, 92:657-671. 10.1161/01.CIR.92.3.657, 7634481.
45. Virmani R, Burke AP, Farb A, Kolodgie FD. Pathology of the vulnerable plaque. J Am Coll Cardiol 2006, 47(8 Suppl):C13-C18.
46. Hattori K, Ozaki Y, Ismail TF, Okumura M, Naruse H, Kan S, Ishikawa M, Kawai T, Ohta M, Kawai H, Hashimoto T, Takagi Y, Ishii J, Serruys PW, Narula J. Impact of statin therapy on plaque characteristics as assessed by serial OCT, grayscale and integrated backscatter-IVUS. JACC Cardiovasc Imaging 2012, 5:169-177. 10.1016/j.jcmg.2011.11.012, 22340823.
47. Fabbri G, Maggioni AP. Cardiovascular risk reduction: what do recent trials with rosuvastatin tell us?. Adv Ther 2009, 26:469-487. 10.1007/s12325-009-0025-6, 19444394.
48. Kjekshus J, Pedersen TR. Reducing the risk of coronary events: evidence from the Scandinavian Simvastatin Survival Study (4S). Am J Cardiol 1995, 76:64C-68C. 10.1016/S0002-9149(99)80473-1, 7572690.
49. Pedersen TR, Olsson AG, Faergeman O, Kjekshus J, Wedel H, Berg K, Wilhelmsen L, Haghfelt T, Thorgeirsson G, Pyorala K, Miettinen T, Christophersen B, Tobert JA, Musliner TA, Cook TJ. Lipoprotein changes and reduction in the incidence of major coronary heart disease events in the Scandinavian Simvastatin Survival Study (4S). Circulation 1998, 97:1453-1460. 10.1161/01.CIR.97.15.1453, 9576425.
50. Grundy SM, Cleeman JI, Merz CN, Brewer HB, Clark LT, Hunninghake DB, Pasternak RC, Smith SC, Stone NJ. Implications of recent clinical trials for the National Cholesterol Education Program Adult Treatment Panel III guidelines. Circulation 2004, 110:227-239. 10.1161/01.CIR.0000133317.49796.0E, 15249516.
51. Tikkanen MJ, Szarek M, Fayyad R, Holme I, Cater NB, Faergeman O, Kastelein JJ, Olsson AG, Larsen ML, Lindahl C, Pedersen TR. Total cardiovascular disease burden: comparing intensive with moderate statin therapy insights from the IDEAL (Incremental Decrease in End Points Through Aggressive Lipid Lowering) trial. J Am Coll Cardiol 2009, 54:2353-2357. 10.1016/j.jacc.2009.08.035, 20082922.
52. Cannon CP, Steinberg BA, Murphy SA, Mega JL, Braunwald E. Meta-analysis of cardiovascular outcomes trials comparing intensive versus moderate statin therapy. J Am Coll Cardiol 2006, 48:438-445. 10.1016/j.jacc.2006.04.070, 16875966.
53. Nissen SE, Tuzcu EM, Schoenhagen P, Crowe T, Sasiela WJ, Tsai J, Orazem J, Magorien RD, O'Shaughnessy C, Ganz P. Statin therapy, LDL cholesterol, C-reactive protein, and coronary artery disease. N Engl J Med 2005, 352:29-38. 10.1056/NEJMoa042000, 15635110.
54. Wenger NK, Lewis SJ, Herrington DM, Bittner V, Welty FK. Outcomes of using high- or low-dose atorvastatin in patients 65 years of age or older with stable coronary heart disease. Ann Intern Med 2007, 147:1-9.
55. Pucci A, Sheiban I, Formato L, Celeste A, Brscic E, Moretti C, De Bernardi A, Alberti A, Bergamasco L, Trevi G, Fuster V. In vivo coronary plaque histology in patients with stable and acute coronary syndromes: relationships with hyperlipidemic status and statin treatment. Atherosclerosis 2007, 194:189-195. 10.1016/j.atherosclerosis.2006.07.026, 16970947.
56. Tokgozoglu L. Dyslipidemia, atherosclerosis, and vulnerable plaques: the effect of atorvastatin on atherosclerosis and plaque structure. Turk Kardiyol Dern Ars 2009, 37:11-16.
57. Imanishi T, Ikejima H, Tsujioka H, Kuroi A, Ishibashi K, Komukai K, Tanimoto T, Ino Y, Takeshita T, Akasaka T. Association of monocyte subset counts with coronary fibrous cap thickness in patients with unstable angina pectoris. Atherosclerosis 2010, 212:628-635. 10.1016/j.atherosclerosis.2010.06.025, 20615506.
58. Kubo T, Akasaka T. Recent advances in intracoronary imaging techniques: focus on optical coherence tomography. Expert Rev Med Devices 2008, 5:691-697. 10.1586/17434440.5.6.691, 19025345.
59. Sharif F, Murphy RT. Current status of vulnerable plaque detection. Catheter Cardiovasc Interv 2010, 75:135-144.
60. Matter CM, Stuber M, Nahrendorf M. Imaging of the unstable plaque: how far have we got?. Eur Heart J 2009, 30:2566-2574. 10.1093/eurheartj/ehp419, 2771148, 19833636.
61. Davidson MH. Clinical significance of statin pleiotropic effects: hypotheses versus evidence. Circulation 2005, 111:2280-2281. 10.1161/01.CIR.0000167560.93138.E7, 15883224.
62. Wang CY, Liu PY, Liao JK. Pleiotropic effects of statin therapy: molecular mechanisms and clinical results. Trends Mol Med 2008, 14:37-44. 10.1016/j.molmed.2007.11.004, 2621332, 18068482.
63. Mihos CG, Santana O. Pleiotropic effects of the HMG-CoA reductase inhibitors. Int J Gen Med 2011, 4:261-271. 3085235, 21556312.
64. Koutouzis M, Nomikos A, Nikolidakis S, Tzavara V, Andrikopoulos V, Nikolaou N, Barbatis C, Kyriakides Z. Statin treated patients have reduced intraplaque angiogenesis in carotid endarterectomy specimens. Atherosclerosis 2007, 192:457-463. 10.1016/j.atherosclerosis.2007.01.035, 17335827.
65. Arnaud C, Mach F. Pleiotropic effects of statins in atherosclerosis: role on endothelial function, inflammation and immunomodulation. Arch Mal Coeur Vaiss 2005, 98:661-666.
66. Vincent L, Chen W, Hong L, Mirshahi F, Mishal Z, Mirshahi-Khorassani T, Vannier JP, Soria J, Soria C. Inhibition of endothelial cell migration by cerivastatin, an HMG-CoA reductase inhibitor: contribution to its anti-angiogenic effect. FEBS Lett 2001, 495:159-166. 10.1016/S0014-5793(01)02337-7, 11334884.
67. Santana O, . Mihos Pleiotropic effects of the HMG-CoA reductase inhibitors. Int J Gen Med 2011, 4:261-271. 3085235, 21556312, Mihos.
68. Fujita M, Yamazaki T, Hayashi D, Kohro T, Okada Y, Nagai R. Pleiotropic effects of statins on cardiovascular events in the Japanese Coronary Artery Disease study. Int J Cardiol 2008, 129:294-296. 10.1016/j.ijcard.2007.06.054, 17655954.
69. Boodhwani M. High-dose atorvastatin improves hypercholesterolemic coronary endothelial dysfunction without improving the angiogenic response. Circulation 2006, 114:I402-I408.
70. Mays ME, Dujovne CA. Pleiotropic effects: should statins be considered an essential component in the treatment of dyslipidemia?. Curr Atheroscler Rep 2008, 10:45-52. 10.1007/s11883-008-0008-0, 18366985.
71. Schwartz GG, Olsson AG, Ezekowitz MD, Ganz P, Oliver MF, Waters D, Zeiher A, Chaitman BR, Leslie S, Stern T. Effects of atorvastatin on early recurrent ischemic events in acute coronary syndromes: the MIRACL study: a randomized controlled trial. JAMA 2001, 285:1711-1718. 10.1001/jama.285.13.1711, 11277825.
72. Wiviott SD, de Lemos JA, Cannon CP, Blazing M, Murphy SA, McCabe CH, Califf R, Braunwald E. A tale of two trials: a comparison of the post-acute coronary syndrome lipid-lowering trials A to Z and PROVE IT-TIMI 22. Circulation 2006, 113:1406-1414. 10.1161/CIRCULATIONAHA.105.586347, 16534008.
73. Ray KK, Cannon CP. Early time to benefit with intensive statin treatment: could it be the pleiotropic effects?. Am J Cardiol 2005, 96:54F-60F. 10.1016/j.amjcard.2005.06.027, 16126024.